Navigation Links
HeartWare to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference

FRAMINGHAM, Mass and SYDNEY, Aug. 12, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to make an investor presentation at the Wedbush Securities 2011 Life Sciences Management Access Conference at 9:10 a.m. Eastern Time on Wednesday, August 17, 2011.  The conference is being held August 16-17, 2011 at Le Parker Meridien in New York City.

A live webcast of the Company's presentation at the conference will be available via a link provided at  An archived replay of the presentation will also be available shortly after the presentation time for 90 days.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.

For further information:
Christopher Taylor
HeartWare International, Inc.
Phone: +1 508 739 0864

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare to Present at the Canaccord Genuity 31st Annual Growth Conference
2. HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010
3. HeartWare to Report Financial Results for Second Quarter of 2011
4. HeartWare to Present at the Wells Fargo 2011 Healthcare Conference
5. HeartWare to Present at the 2011 Bank of America Merrill Lynch Health Care Conference
6. HeartWare International Reports First Quarter 2011 Revenues of $18.0 Million; 68% Increase From $10.7 Million in First Quarter 2010
7. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
8. HeartWare Announces Presentations at The International Society of Heart and Lung Transplantation Annual Meeting
9. HeartWare International Receives Approval From the Therapeutic Goods Administration (TGA) in Australia
10. HeartWare to Present at the Barclays Capital 2011 Global Healthcare Conference
11. HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009
Post Your Comments:
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology:
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):